Head to Head Analysis: Akebia Therapeutics (NASDAQ:AKBA) versus XTL Biopharmaceuticals (NASDAQ:XTLB)

XTL Biopharmaceuticals (NASDAQ:XTLB) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Profitability

This table compares XTL Biopharmaceuticals and Akebia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Insider and Institutional Ownership

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

XTL Biopharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for XTL Biopharmaceuticals and Akebia Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
Akebia Therapeutics	1	2	4	0	2.43

Akebia Therapeutics has a consensus target price of $3.90, indicating a potential upside of 318.19%. Given Akebia Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than XTL Biopharmaceuticals.

Valuation & Earnings

This table compares XTL Biopharmaceuticals and Akebia Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	11.96	-$6.97 million	($0.64)	-3.55
Akebia Therapeutics	$236.20 million	1.09	-$5.34 million	($0.11)	-8.48

Akebia Therapeutics has higher revenue and earnings than XTL Biopharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than XTL Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.